Literature DB >> 3197348

Transmission of HIV and AIDS by plasmapheresis for Guillain-Barré syndrome.

C A Boucher1, J de Gans, R van Oers, S Danner, J Goudsmit.   

Abstract

A 58-year-old patient suffering from Guillain-Barré syndrome was successfully treated with plasma exchange therapy. Two- and half year later she developed AIDS. The only risk factor of this patient was plasmapheresis and it appeared, retrospectively, that one of the plasma donor samples contained antibodies to HIV. Knowing the exact moment of infection of our patient we documented the transfer of HIV antibodies from donor to patient, a HIV antigen peak two weeks after transmission (reflecting the initial virus replication in the patient) and subsequently the occurrence of patients' HIV antibodies and the reoccurrence of HIV antigen at the moment AIDS was diagnosed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3197348     DOI: 10.1016/0303-8467(88)90027-3

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  5 in total

Review 1.  [Plasma exchange as a therapeutic option in neurological disorders].

Authors:  H C Lehmann; H P Hartung; G R Hetzel; B C Kieseier
Journal:  Nervenarzt       Date:  2007-02       Impact factor: 1.214

2.  [Immunotherapy and infectious issues in multiple sclerosis. Self-injectable and oral drugs for immunotherapy].

Authors:  A Winkelmann; M Löbermann; E C Reisinger; H-P Hartung; U K Zettl
Journal:  Nervenarzt       Date:  2015-08       Impact factor: 1.214

Review 3.  Disease-modifying therapies and infectious risks in multiple sclerosis.

Authors:  Alexander Winkelmann; Micha Loebermann; Emil C Reisinger; Hans-Peter Hartung; Uwe K Zettl
Journal:  Nat Rev Neurol       Date:  2016-03-04       Impact factor: 42.937

4.  Complications of plasma exchange in patients with neurological diseases.

Authors:  T Henze; H W Prange; J Talartschik; K W Rumpf
Journal:  Klin Wochenschr       Date:  1990-12-04

Review 5.  Multiple sclerosis treatment and infectious issues: update 2013.

Authors:  A Winkelmann; M Loebermann; E C Reisinger; U K Zettl
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.